Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS: Shire Income Up In 2nd-Quarter Ahead Of Takeover By Takeda

Tue, 31st Jul 2018 12:51

LONDON (Alliance News) - Irish biotechnology company Shire PLC on Tuesday posted a more than doubled pretax income in the second quarter, ahead of its upcoming takeover by Takeda Pharmaceutical Co Ltd.

In the three months to June 30, Shire recorded pretax income from continuing operations, excluding equity earnings, of USD734.2 million. This compares with a USD261.5 million income for the same quarter in 2017.

The company's revenue for the period was USD3.92 billion, up from USD3.75 billion the year before. Product sales made up the bulk of this, increasing 6% to USD3.81 billion from USD3.59 billion.

Immunology led product sales growth, climbing 13%, alongside a 61% rise in internal medicine sales and a 75% growth in Ophthalmics sales.

Royalties and other revenue dropped 28% to USD111 million from USD154 million due to lower royalties from thyroid drug Sensipar.

Revenue from ADHD drug Adderall XR was reclassified to product sales from royalty revenue, alongside other changes under the new accounting standard.

The company said that it will pay a dividend per share of 5.60 US cents for the interim, up 10% from 5.09 cents in 2017.

Shire intends to sell its oncology franchise to Servier SAS in the upcoming third quarter of 2018. At present, Shire's guidance 2018 is unchanged but it will be updated once the franchise is sold. The company said its 2020 guidance is likewise unchanged but has yet to be updated to include the sale of oncology.

"During the quarter, our board reached an agreement with the Takeda board on the terms of a recommended offer for Takeda to acquire Shire. The acquisition is expected to close in the first half of 2019, subject to shareholder approval of both companies and additional regulatory approvals. In the meantime, we remain resolutely focused on execution as these results demonstrate," said Shire Chief Executive Flemming Ornskov.

Shire agreed a takeover by Takeda in early May and gained unconditional clearance from the US Federal Trade Commission at the start of this month. The deal values Shire at GBP46.00 billion.

Shares in Shire were up 0.5% at 4,335.00 pence on Tuesday.

More News
30 Nov 2018 07:38

LONDON MARKET PRE-OPEN: Ecolab To Acquire Bioquell For GBP141 Million

LONDON (Alliance News) - Stock prices in London are seen opening marginally lower on Friday as investors await a meeting of US and Chinese leaders at the G20 summit.IG futures indicate the FTSE is

Read more
30 Nov 2018 07:23

Shire gets EC approval for hereditary angioedema jab

(Sharecast News) - Shire's injectable treatment for hereditary angioedema (HAE) has been cleared for launch in European, having enjoyed early success in the US.

Read more
28 Nov 2018 07:53

Shire's Lanadelumab Help Study Meets Primary And Secondary Endpoints

LONDON (Alliance News) - Shire PLC said Tuesday it has published the full results of its phase III Help study of its hereditary angioedema drug Lanadelumab showing that the study met all of its is

Read more
20 Nov 2018 14:34

EU clears Takeda's Shire acquisition on divestment condition

(Sharecast News) - The European Commission has cleared Takeda Pharmaceutical's £46bn acquisition of Shire, subject to the divestment of a bowel disease drug under development by Shire.

Read more
1 Nov 2018 12:48

TOP NEWS: Shire Revenue Climbs On Strong Performance From Immunology

LONDON (Alliance News) - Shire PLC on Thursday updated its guidance and said its revenue grew in the third quarter of of 2018 as a result of strong Immunology division growth, recent product and a

Read more
1 Nov 2018 12:09

Shire sales remain solid, Takeda deal 'on track'

(Sharecast News) - Shire Pharmaceuticals, the subject of a $62bn takeover by Japan's Takeda, said its focus on rare diseases had offset foreign exchange weakness and boosted third-quarter profits.

Read more
1 Nov 2018 08:48

LONDON MARKET OPEN: Oil Stocks And Strong Pound Weigh On FTSE 100

LONDON (Alliance News) - Stocks in London opened mixed on Thursday, with heavyweight oil majors and a stronger pound hampering the FTSE 100, ahead of the Bank of England's interest rate decion

Read more
31 Oct 2018 06:11

Takeda's raises full-year outlook after Q2 profit rise

TOKYO, Oct 31 (Reuters) - Takeda Pharmaceutical Co Ltd on Wednesday raised its annual operating profit outlook to 268.9 billion yen. That compares with an earlier company estimate of yen an

Read more
29 Oct 2018 12:19

Takeda proposes selling off Shire drug to gain merger clearance

(Sharecast News) - Takeda Pharmaceuticals may need to sell off one of Shire's pipeline drugs in order to gain European regulatory clearance for the agreed $62bn takeover.

Read more
29 Oct 2018 12:19

Takeda proposes selling off Shire drug to gain merger clearance

(Sharecast News) - Takeda Pharmaceuticals may need to sell off one of Shire's pipeline drugs in order to gain European regulatory clearance for the agreed $62bn takeover.

Read more
29 Oct 2018 10:51

WINNERS & LOSERS SUMMARY: HSBC Rises After Upbeat Third Quarter

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------HSBC,

Read more
29 Oct 2018 07:35

LONDON MARKET PRE-OPEN: Better-Than-Expected HSBC To Lift FTSE 100

LONDON (Alliance News) - Stocks in London are set to open on firmer ground on Monday, following last week's sell-off, while traders eye Chancellor Philip Hammond's UK government shares in in

Read more
26 Oct 2018 07:52

Takeda Secures JPY1 Trillion Of Financing To Help Shire Deal

LONDON (Alliance News) - Japan's Takeda Pharmaceuticals Inc on Friday said it has secured new financing to help it with its acquisition of FTSE 100 member Shire PLC.The new short-term a

Read more
25 Oct 2018 16:21

Shire hopes to get green light for US Flexbumin manufacture

(Sharecast News) - Shire on Thursday filed a submission to the US food and drug administration to gain approval to manufacture Flexbumin at its new facility in the state of Georgia.

Read more
25 Oct 2018 16:03

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 26 October GlencoreQ3 ProductionInternational Consolidated Airlines GroupQ3 Bank 1

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.